Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Urologix targets wider BPH (benign prostatic hyperplasia) market:

This article was originally published in Clinica

Executive Summary

Urologix has released a version of its Cooled ThermoTherapy treatment for benign prostatic hyperplasia (BPH) that will allow it to target its therapy to more patients, the Minneapolis, Minnesota firm reports. The new product comprises a shorter length catheter designed to treat the estimated 15-20% of patients that have smaller prostates and will complement the firm's standard catheter, which is indicated for patients with medium to larger prostates. Cooled ThermoTherapy delivers microwave energy into the prostate while using a cooling process that minimises the effect on surrounding tissue.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel